ArmaGen Technologies Gets $17M For Protein Therapeutics

Santa Monica-based biopharmaceuticals startup ArmaGen Technologies announced Thursday afternoon tha tit has raised $17M in a Series A financing round. The firm said it is developing brain-penetrating recombinant protein therapeutics, which allows biopharmaceuticals to reach the central nervous system more effectively. The funding was led by Boehringer Ingelheim Venture Fund, and also included Shire plc, Takeda Ventures, Inc., and Mitsui & Co. Global Investment. ArmaGen's products are aimed at getting past the blood-brain barrier, a feature of the human body which makes it difficult for bacteria and viruses to invade the brain--but also, makes it very difficult to deliver pharmaceuticals to the central nervous system. More information »